1

COVID-19 Vaccination Uptake and Self-Reported Side Effects among Healthcare 2 Workers in Mbale City Eastern Uganda

3 **Authors:**

- 4 Gabriel Madut Akech¹, Andrew Marvin Kanyike¹, Ashah Galabuzi Nassozi¹, Beatrice Aguti¹,
- Ashley Winfred Nakawuki², Denis Kimbugwe², Josen Kiggundu³, Robert Maiteki², Dorothy 5
- 6 Mukyala², Felix Bongomin⁴, Samuel Baker Obakiro⁵, Nekaka Rebecca⁶, Jacob Stanley
- 7 Iramiot⁷

Affiliations: 8

- 9 1. Faculty of Health Sciences, Busitema University, Mbale, Uganda
- 2. Mbale Regional Referral Hospital, Ministry of Health, Uganda 10
- 11 3. Ministry of Health/AIDS Control Program, Kampala, Uganda
- 12 4. Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu 13 University, Gulu, Uganda
- 14 5. Department of Pharmacology and Therapeutics, Faculty of Health Sciences, Busitema 15 University, Mbale, Uganda
- 16 6. Department of Public Health, Faculty of Health Sciences, Busitema University,
- 17 Mbale, Uganda
- 7. Department of Microbiology and Immunology, Faculty of Health Sciences, Busitema 18 19 University, Mbale, Uganda
- 20

21 **Corresponding Author**

- 22 Gabriel Madut Akech
- 23 Faculty of health sciences, Busitema University, Mbale, Uganda
- 24 Akechgabriel93@gmail.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 ABSTRACT

Background: Fear of anticipated side effects has hindered the COVID-19 vaccination program globally. We report the uptake and the self-reported side effects (SEs) of the COVID-19 vaccine among Healthcare workers (HCWs) in Mbale City Eastern Uganda. Methods: A cross-sectional survey of HCWs at seven different level health facilities was conducted from 6th September to 7th October 2021 using a structured self-administered questionnaire.

- 32 **Results:** COVID-19 vaccine had been received by 119 (69%) participants of which 79 (66%)
- 33 received the two recommended doses of the AstraZeneca vaccine. Getting vaccinated was
- 34 associated with working in a lower health facility (aOR= 14.1, 95% CI: 4.9 39.6, P=0.000),
- 35 perceived minor risk of contracting COVID-19 (aOR= 12.3, 95% CI: 1.0 44.6, p=0.047),
- and agreeing that COVID-19 vaccine is protective (aOR= 16.7, 95% CI: 5.6 50.4, p=0.000).
- 37 97 (82%) of participants experienced side effects to at least one dose of which most were
- mild on both the first (n=362, 51%) and second dose (n=135, 69%). The most frequently
- 39 reported side effects on the first and second dose were fever (79% and 20%), injection site
- 40 pain (71% and 25%), and Fatigue (69% and 20%) respectively.
- 41 **Conclusions:** The majority of the HCWs in Mbale City had received at least one dose of the
- 42 COVID-19 vaccine and experienced a side effect. The side effects were mostly mild on either
- 43 dose thus the vaccines are generally safe.
- Keywords: COVID-19 vaccine, associated factors, side effects, healthcare workers, Eastern
 Uganda.

46 **INTRODUCTION**

47 Coronavirus disease-2019 (COVID-19) is a viral pneumonia caused by the novel SARS-48 CoV-2 which was first reported in Wuhan, China in December 2019 and continues to pose a 49 significant threat to public health globally (1). As of 26th November 2021, over 260 million 50 cases and over 5.2 million deaths have been reported worldwide (Worldometer, 2021). In 51 Uganda, the first case of COVID-19 was reported on 21st March 2020 (3), and as of 26th 52 November 2021, over 126,965 cases and about 3,239 deaths reported (Ministry of Health 53 Uganda, 2021).

- 54 At the moment, no single effective therapeutic agent has been approved for the treatment of
- 55 COVID-19. However, several public health measures like social distancing, national-wide
- 56 lockdowns, and hand-washing among others have been employed to control the pandemic(5).
- 57 Despite these measures, COVID-19 remains a major public health challenge with some
- 58 countries experiencing the third and fourth waves (5). Currently, vaccination against SARS

59 CoV-2 is thought to be the best public health measure to halt the COVID-19 pandemic (6).

60 There are currently several COVID-19 vaccine candidates with at least 8 vaccines approved

- 61 for use by the World Health Organization. These include Moderna (mRNA-1273),
- 62 Pfizer/BioNtech (BNT162b2), Jansen (ad26.COV2.S), Oxford/AstraZeneca (AZD1222),
- 63 Covishield (Oxford/AstraZeneca formulation), Covaxin (Bharat Biotech), Sinopharm (BBIP-
- 64 CorV), and Sinovac (CoronaVac) (7,8).

This first roll out of COVID-19 vaccinations was considered a land mark for overcoming the pandemic (9,10). However vaccination has long been faced with hesitancy due to public worries about side effects (SEs) and efficacy (11), which is worse with COVID-19 surrounded by conspiracies. The COVID-19 vaccines have however been reported by various clinical trials to be generally safe with limited side effects that are mild to moderate with a few severe reactions (12–15).

Healthcare workers (HCWs) are not only a high-risk group but also offer guidance on vaccine recommendations to the public which relies on them for this information (16,17). Automatic uptake of the COVID-19 vaccine by HCWs is not guaranteed as a study done in Israel, reported a high rate of COVID-19 vaccine skepticism among this group (18). Vaccination compliance relies on a personal risk–benefit perception, and broader political, religious, social, and historical factors (17).

Also, most data about side effects of the COVID-19 vaccines comes from manufacturerfunded studies in compliance with drug regulatory authorities which warrants continuous monitoring of adverse events (9,19). Ever since Uganda rolled out its vaccination program, no study has been published about the side effects of the vaccine among those that have received it. Therefore, we determined the uptake of the COVID-19 vaccine and self-reported side effects among healthcare workers in Mbale city, Eastern Uganda.

83 Methods

84 Study Design

This was a descriptive, cross-sectional study carried out from 6th September to 7th October 2021 using a quantitative approach.

87 Study Setting

This study was carried out in seven health facilities in Mbale city, including six government facilities; Mbale regional referral hospital, Namatala Health centre IV, Malukhu Health Centre III, Namakwekwe Health Centre III, Busamaga Health Centre III, Mbale Municipal Health Centre II and The AIDS Support Organization (TASO) Mbale Centre of excellence a

92 private-not-for-profit facility. Uganda's health system has both public and private sector 93 which has private-for-profit and private-not-for-profit facilities. The public health sector is 94 divided into national (governed by the ministry of health) and district (governed by district health management team) based level facilities. The national level consists of national 95 96 referral hospitals at the top then regional referral hospitals. The district level has the district 97 hospitals at the helm followed by health centers IV.III, II and community extension health workers called Village health team (VHTs) serving as level I. Mbale city is located in the 98 99 Eastern region of Uganda. Mbale Regional Referral Hospital is a tertiary hospital—serving 100 the districts of Busia, Buddaka, Kibuku, Kapchorwa, Bukwa, Butaleja, Manafwa, Mbale, 101 Pallisa, Sironko, budduda, Bukedea and Tororo(20). It's a 470-bed capacity hospital and serves as a teaching hospital for Busitema University Faculty of Health Sciences as well as an 102 103 Internship center for graduates from medical schools for a one-year internship under the 104 supervision of qualified specialists and Consultants.

105 Study Population

106 Healthcare workers in the selected facilities were involved in the study. A healthcare worker 107 was considered as any person engaged in activities whose primary role is to improve the health of patients including nurses, midwives, intern doctors, medical officers, senior house 108 109 officers, pharmacists, laboratory technicians and specialists in the field of medicine. Mbale Regional Referral Hospital (MRRH) had a total of 243 permanent HCWs and 57 interns on a 110 111 temporary one-year contract. The other five lower health centers had a total of 120 trained 112 health care workers of different cadres. TASO Mbale Centre of excellence had 31 full- time 113 staff. This makes a total of about 451 health care workers in primary contact with patients 114 within the selected health facilities in Mbale city currently.

115 Inclusion and Exclusion Criteria

HCWs at selected health facilities within Mbale city who consented to participate were included and those that didn't consent or were absent on duty were excluded.

118 Sampling Procedure and Data collection

The research followed a proportional stratified random sampling technique. The study 119 120 population was stratified by level of health facility each taking a proportion depending on the 121 percentage contribution to the total required sample size. Participants were enrolled by 122 random sampling at that particular time data was collected at the facility. Data was collected using semi-structured questionnaire that was provided by research assistants at each facility. 123 The research assistants were trained on the unique aspects of the study via a zoom session 124 after they had been identified. Questionnaires were administered by hardcopy after informed 125 126 consent had been given by the participant.

127 Data Collection tool

We used a modified questionnaire based on those that were used by other scholars. The questionnaire was semi-structured with 28 questions divided into five sections capturing socio-demographic information of participants, COVID-19 related experiences and attitudes towards COVID-19 vaccine, its uptake, and self-reported side effects among health workers

132 that have taken the vaccine.

133 Data Analysis

Data from completed questionnaires were entered in Microsoft Excel 2016, cleaned, coded and analyzed using STATA 16. Descriptive statistics, and bivariate and multivariable logistic regression analyses were performed, and results were presented as tables, charts and figures. Chi-square or Fisher's exact test was used to assess associations between vaccine uptake and independent variables. An association with a p-value less than 0.05 was considered statistically significant.

140 **Results**

141 **Baseline characteristics of the participants**

142 One hundred seventy-two (172) participants were interviewed giving a 45% response rate.

143 Most were female (n=95, 55%), married (n=90, 52%), with a median age of 31 (IQR: 25-39)

144 years. Most participants were from Mbale Regional Referral Hospital (n=92, 53%). Forty-

three (25%) participants were nursing officers and the minority were specialists (n=6, 3%),

146 (Table 1).

147	Table 1:	Demograp	hic charac	teristic of	participants	(N=172)
14/	Table 1.	Demograpi	ne charac		participants	(11 - 1/2)

VARIABLE	Frequency	Percentage
Age (Median; IQR), years	31 (25-39)	
18-39	130	76
≥40	42	24
Sex		
Female	95	55
Male	77	45
Marital status		
Single	76	44
Married	90	52
Divorced/Separated	1	1
Widowed	5	3
Religion		
Roman catholic	46	27
Anglican	59	34
Pentecostal	42	24

Muslim	24	14
Others	1	1
Cadre		
Medical officer	15	9
Nursing officer	43	25
Pharmacist	3	2
Midwife	38	22
Interns	42	24
Laboratory technician	15	9
Specialists	6	3
Clinical Officers	8	5
Counsellors	2	1
Health Facility		
Health center II	13	8
Health center III	41	24
Health center IV	20	12
Mbale Regional Referral Hospital	92	53
Private Not for Profit	6	3

148

149 COVID-19 vaccine uptake among healthcare workers

The majority of the participants (n=119, 69%) had received at least one dose of the COVID-19 vaccine. Of these, 79 (66%) had received two doses. The major reason for being vaccinated was to protect oneself (n=95, 79%) and others (n=62, 52%) from COVID-19. Among unvaccinated participants, the majority (n=21, 40%) were still hesitant and not sure whether they majority will take it in future. The major reasons for not accepting to be vaccinated against COVID-19 were uncertainty about the vaccine safety (n=31, 55%), and negative information about the vaccine (n=30, 54%), (Table 2).

157 Table 2: COVID-19 vaccine uptake and reasons for and against among participants

Have you been vaccinated against COVID-19?	Frequency	Percentage
Yes	119	69
No	53	31
The number of COVID-19 vaccine doses received.		
One Dose	40	34
Two Doses	79	66
Are you intending to take the COVID-19 vaccine in the		
future?		
Yes, I will get vaccinated	18	34
I am not sure	21	40
No, I will not get vaccinated	14	26
Reasons for COVID-19 vaccine uptake		
To protect me from getting COVID-19	95	79
To protect others from getting COVID-19	62	52
I believe in vaccines and immunization	48	40
Government recommendations	64	53

Because my colleague had taken it	7	6
The vaccines are safe	42	35
	36	30
The vaccines are effective		
It is a social and moral responsibility	25	21
The vaccine was free of charge	38	32
To be able to travel	31	26
I am at high risk of severe disease	30	25
To get rid of the virus and end the pandemic	25	21
It's a job requirement	38	32
It's my obligation as a healthcare worker to motivate	61	51
others	01	51
Reasons for not getting the COVID-19 vaccine		
I don't think it is needed	12	21
I trust my immunity	18	32
I don't know where to get the vaccination	1	2
I don't know where to get good/reliable information	4	7
I have heard or read negative information on the vaccine.	30	54
I don't think the vaccine is effective	24	43
I don't think the vaccine is safe/concerned about side	21	55
effects	31	55
Someone else told me that the vaccine is not safe	9	16
Had a bad experience with a previous vaccinator/health	2	4
clinic	2	4
Had a bad experience or reaction to previous vaccination	6	11
Someone else told me they/their child had a bad reaction	12	21
Fear of needles	2	4
Religious reasons	4	7
Other beliefs/traditional medicine	3	5

158

159 Factors associated with COVID-19 vaccine uptake among health workers

160 At bivariable analysis, age (p=0.002), marital status (p=0.019), the cadre of the staff 161 (p<0.001), level of health facility (p<0.001), belief in the effectiveness of the COVID-19 162 vaccine (p<0.001) and having a chronic illness (p=0.021) were statistically significantly 163 associated with COVID-19 vaccine uptake, Table 3.

164 **Table 3: Uptake of COVID-19 vaccine and associated factors among the participants**

VARIABLE	COVID-19 VACCINE UPTAKE		P-VALUE
	YES	NO	
	Frequency (%)	Frequency (%)	
All participants	119 (69)	53 (31)	
Age, years			
18-39	82 (70)	48 (91)	0.002
≥40	37 (30)	5 (9)	0.002
Sex			
Female	66 (55)	29 (55)	0.928
Male	53 (45)	24 (45)	0.928

Marital status			
Single	45 (38)	31 (58)	
Married	68 (57)	22 (42)	0.019
Separated	6 (5)	0 (0)	
Religion			
Roman Catholic	36 (30)	10 (19)	
Anglican	40 (34)	19 (36)	
Pentecostal	27 (23)	15 (28)	0.454
Muslim	15 (13)	9 (17)	
Others	1(1)	0 (0)	
Cadre			·
Medical officer	11 (9)	4 (8)	
Nursing officer	35 (29)	8 (15)	
Pharmacist	2 (2)	1 (2)	
Midwife	30 (25)	8 (15)	
Interns	15 (13)	27 (51)	<0.001
Laboratory technician	13 (11)	2 (4)	
Specialists	6 (5)	0 (0)	
Clinical Officers	5 (4)	3 (6)	
Counsellors	2 (2)	0 (0)	
Health Facility		· · ·	
Lower Health Facility	66 (55)	8 (15)	<0.001
Hospital	53 (45)	45 (85)	<0.001
Perceived likelihood of ge	tting COVID-19 in t	he future?	·
Not at all	27 (23)	21 (40)	
Slightly	48 (40)	16 (30)	0.072
Very likely	44 (37)	16 (30)	
Overall worry about COV	/ID-19?		
Very worried	49 (41)	19 (36)	
Somewhat worried	52 (44)	21 (40)	0.332
Not at all worried	18 (15)	13 (25)	
Perceived COVID-19 pers			
Major risk	71 (60)	33 (62)	
Minor risk	44 (37)	14 (26)	0.072
No risk at all	4 (3)	6 (11)	
Have you been tested for	COVID-19?		
Tested positive	8 (7)	7 (13)	
Tested negative	60 (50)	17 (32)	0.060
Haven't tested	51 (43)	29 (55)	
Active involvement in CO	VID-19 managemen	t	
Yes	66 (55)	23 (43)	0.144
No	53 (45)	30 (57)	0.144
COVID-19 vaccine gives e	ffective protection	;	
Agree	73 (61)	11 (21)	
Neutral	15 (13)	9 (17)	<0.001
Disagree	31 (26)	33 (62)	
Chronic illness			
Yes	23 (19)	3 (6)	0.021
No	96 (81)	50 (94)	0.021

165

- 166 At multivariable analysis, factors independently associated with uptake of the COVID-19
- 167 vaccine were as follows: working in a lower health facility (aOR= 14.1, 95% CI: 4.9 39.6,
- 168 P=0.000), individual perceived minor risk of contracting COVID-19 (aOR= 12.3, 95% CI:
- 169 1.0 44.6, p=0.047), and agreeing that COVID-19 vaccine is protective (aOR= 16.7, 95% CI:
- 170 5.6 50.4, p=0.000), (Table 4).

171 Table 4: Multivariate logistic regression for factors associated with COVID-19 vaccine

172 uptake among participants.


VARIABLE	OR (95% CI)	P-VALUE	AOR (95% CI)	P-VALUE
Age				
18-39	Ref		Ref	
40 years and above	4.3 (1.6 – 11.8)	0.004	2.7 (0.7 – 10.2)	0.136
Marital Status		•		
Single	0.5 (0.2 - 0.9)	0.026	0.6 (0.2 – 1.6)	0.353
Separated	Ref		Ref	
Cadre				
Medical officer	1.2(0.2-6.9)	0.856		
Nursing officer	1.9(0.4 - 8.9)	0.428		
Pharmacist	0.9(0.1 - 13.4)	0.913		
Midwife	1.6(0.3-7.7)	0.551		
Interns	0.2(0.1-1.1)	0.059		
Laboratory technician	2.8(0.4-20.8)	0.318		
Specialists	Ref			
Health Facility			1	-
	1	1	1	1
Lower Health Facility	7.0 (3.0 – 16.1)	0.000	14.1 (4.9 – 39.6)	0.000
Hospital	Ref		Ref	
Perceived likelihood of g	otting COVID 105	 in the future?	 }	
Not at all	Ref		Ref	
	2.3(1.0-5.2)	0.039	1.8 (0.5 - 5.8)	0.360
Slightly Very likely	2.3(1.0-3.2) 2.1(0.9-4.8)	0.039	1.3(0.3-5.8) 1.3(0.4-4.4)	0.300
<u> </u>		0.003	1.5 (0.4 - 4.4)	0.077
Perceived COVID-19 per	3.2 (0.9 - 12.2)	0.004	82(00 082)	0.007
Major risk Minor risk		0.084	8.2(0.9-98.2)	0.097
No risk at all	$\begin{vmatrix} 4.7 & (1.2 - 19.1) \\ \text{Ref} \end{vmatrix}$	0.030	12.3 (1.0 – 44.6) Ref	0.047
			Kel	
Have you been tested for		0.447		
Tested positive	0.6(0.2-1.9)	0.447		
Tested negative	2.0(0.9-4.1)	0.053		
Haven't tested	Ref			
COVID-19 vaccine gives	-	1	1(7(5(50 4)	0.000
Agree	7.1(3.2-15.7)	0.000	16.7(5.6-50.4)	0.000
Disagree	1.8(0.7-4.6)	0.242	1.3(0.3-4.9)	0.728
Neutral	Ref		Ref	
Active involvement in C		1		
Yes	1.6(0.8-3.1)	0.145		
No	Ref			

Chronic illness				
Yes	4.0 (1.1 – 13.9)	0.030	3.1 (0.6 - 15.0)	0.168
No	Ref		Ref	

173

174 Self-reported side-effects among covid-19 vaccine recipients


The majority of the COVID-19 vaccine recipients (n=97, 82%) experienced side-effects of at least one dose of the vaccine which lasted for a median duration of 3 (IQR: 3-7) days. All recipients (n=97, 100%) experienced at least one side effect on their first dose of vaccination and only thirty-eight (39%) on the second dose, Figure 2. Most of the side-effects were mild on both the first (n=362, 51%) and second dose (n=135, 69%). Severe side-effects were experienced more on the first (11%) than second (7%) dose (Figure 3).



182 Figure 2: Occurrence of self-reported side-effects on the different vaccine doses

183


181



185 Figure 3: Severity of self-reported side-effects on the different vaccine doses186

184


The most frequently reported side-effects of the first and second dose were fever (79% and20%), injection site pain (71% *and* 25%) and Fatigue (69% *and* 20%) respectively, Figure 4. Participants who had ever tested positive for COVID-19 experienced side effects for a longer duration (median= 7, IQR: 3-11 days) compared to those who had either tested negative (median= 5, IQR: 3—5 days) or had never tested (median= 3, IQR: 3-5 days). There was no statistically significant difference in the duration of side-effects among the different age groups (Figure 5).





205 Figure 4: The different self-reported side effects on both COVID-19 vaccine doses

206



2 Figure 5: Duration of self-reported side-effects compared among (a) outcomes of previous COVID-19 test (b) possession of chronic illness and (c) age category. Median duration of side-effects is 3 days 2

DISCUSSION 217

218 Health Care Workers (HCWs) being at the frontline in the fight against the pandemic are at a

219 high risk of contracting COVID-19 as they provide medical services to COVID-19 patients. 220 (21). As a result several HCWs have succumbed to COVID-19, with variable morbidity and

221 mortality reported from different countries (22). In the COVID-19 vaccination programs of

222 most countries in low- and middle-income countries (23). HCWs have been prioritized due to 223 the limited supply of the COVID-19 vaccine. Despite this, COVID-19 vaccine hesitancy has 224 been reported globally, including among HCWs and the WHO reports it among the top 10 225 global threats to health (18).

In this study, a high proportion (79%) of HCWs had received at least one dose of the 226 227 COVID-19 vaccine. Our findings are similar to the 71.1% COVID-19 vaccine uptake 228 reported in 19 countries among healthcare workers (24). However, in contrast, lower vaccine 229 acceptability was reported in the U.S.A (36%) (16) and Turkey (31%) (25). Higher 230 acceptability rates have been reported among HCWs in France (81.5%) (23), Mozambique 231 (88.6%) (26) China (91.3%) (27), and Indonesia (95%) (28). It's reasonable that Asian 232 countries like China which was hit hard by the pandemic reported higher uptake of the vaccine. The participants that believed that the vaccine was effective were twenty-eight times 233

234 more likely to get vaccinated. This finding is in line with another study where participants 235 who believed that COVID-19 vaccination, is an effective way to prevent and control COVID-236 19 tended to accept COVID-19 vaccination as soon as possible (18). Furthermore, HCWs who perceived a major risk of contracting COVID-19 and had previously tested negative for 237 238 COVID-19 took up the vaccine. Indeed in a multicenter study, Evridiki et al reported that 239 increased risk perception towards COVID 19 was associated with the likely uptake of the 240 COVID-19 vaccine (29). Working at a lower health facility had 25 -fold higher odds of 241 uptake of the COVID-19 vaccine.

242 In this study, most of the side effects reported were mild (51%) in correspondence with the 243 known side effects of the AstraZeneca vaccine (12–15). Most reported side effects included 244 fever, injection site pain, and fatigue, and this is in line with a systematic review that reported 245 the same adverse effects from various clinical trials (9,30). Participants reported more severe 246 side effects with the first than the second dose in contrast to Mathioudakis et al who noted more side effects with the second dose (10). After the first vaccine dose, the body gets 247 248 sensitized to the antigens and a severe immune reaction is expected on the booster dose. 249 Probably most of the vaccine recipients could have been infected at the time of vaccination 250 with sensitized immune systems that reacted severely to re-exposure of the virus since prior testing to vaccination wasn't done. To further reinforce that, participants who had ever 251 252 tested positive for COVID-19 experienced a longer duration of symptoms compared to those 253 who tested negative.

254 Limitations and Strengths

The study provides results from multiple health facilities, and information about the relatively real-world safety profiles of the AstraZeneca vaccine in Uganda. However, this study has some limitations; the sample size is relatively small and was conducted mainly in an urban setting in a single city thus the findings may not be confidently generalizable to the rest of the country. Future studies involving a larger sample size are recommended to provide a complete side-effects profile of COVID-19 vaccines among recipients in Uganda.

261 Conclusion

In conclusion, our findings have shown high levels of uptake of the COVID-19 vaccine among HCWs in Mbale city. At least four-fifth of HCWs experienced at least one SE after receiving the COVID-19 vaccine. Most of the side effects were mild and the same as those seen in other commonly provided vaccines therefore the vaccines are generally safe and can be taken by the public with confidence.

267 Funding

268 This study was funded by the Fogarty International Center of the National Institutes of

269 Health, U.S. Department of State's Office of the U.S. Global AIDS Coordinator and Health

- 270 Diplomacy (S/GAC), and President's Emergency Plan for AIDS Relief (PEPFAR) under
- Award Number IR25TW011213.

272 **Declaration of competing interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health

- 277 Consent for publication
- 278 Not applicable

279 Ethical Consideration

The proposal was submitted for ethical review and approved by the Research Ethics Committee of Cure Children's Hospital Uganda (CCHU-REC) under approval number CCHU-REC/02/2021. Additional permission was requested from the administration of the health facilities where the study was carried out and all participants provided an informed consent. The ethical principles of involvement of human research subjects as outlined in the *Nuremberg Code* and the *Declaration of Helsinki* were strictly adhered to.

286 Authors' contributions

This study was carried out with considerable contributions from all authors. Author FB, AMK, AGN, BA, AWN, GMA, RM, JSI and SBO, conceptualized and design the study protocol. Author AMK, GMA, AGN, BA, AWN, DK, JK, RM, and DM, participated in data collection. AMK, FB, GMA and JSI analyzed the data. Author GMA and AMK drafted the first manuscript, NK and JSI conducted critical reviews. All authors reviewed and approved the final manuscript.

293 Authors' Details

¹Faculty of Health Sciences, Busitema University, Mbale, Uganda, ²Mbale Regional Referral
Hospital, Ministry of Health , Uganda, ³Ministry of Health/AIDS Control Program, Kampala,
Uganda, ⁴Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu
University, Gulu, Uganda, ⁵Department of Pharmacology and Therapeutics, Faculty of Health
Sciences, Busitema University, Mbale, Uganda, ⁶Department of Public Health, Faculty of
Health Sciences, Busitema University, Mbale, Uganda, ⁷Department of Microbiology and
Immunology, Faculty of Health Sciences, Busitema University, Mbale, Uganda

301

302 REFERENCES

303	1.	Al-mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi
304		Arabia : A Web-Based National Survey. 2020;1657–63.

- 305 2. Worldometer. COVID-19 Virus Pandemic Updates.
- 306 3. Ajari EE, Kanyike AM, Ojilong D, Abdulbasit IO. COVID-19 in Uganda:
- 307 Epidemiology and Response. Eur J Med Educ Technol. 2020;13(2):em2009.
- 308 4. Ministry of Health Uganda. MOH COVID-19 Information Portal. 2020.
- 309 5. Looi MK. Covid-19: Is a second wave hitting Europe? BMJ. 2020;371:4113.
- Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated
 vaccine candidate for SARS-CoV-2. 2020;81(July):77–81.
- 312 7. Hiller N, Goldberg SN, Cohen-Cymberknoh M, Vainstein V, Simanovsky N.
- 313 Lymphadenopathy Associated With the COVID-19 Vaccine. Cureus. 2021 Feb;13(2).
- Kadali RAK, Janagama R, Peruru S, Gajula V, Madathala RR, Chennaiahgari N, et al.
 Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional
 study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021
 Apr;jmv.26996.
- Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID 19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin
 Med. 2021 Apr;10(7):1428.
- Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP,
 et al. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines : A
 Vaccine Recipient Survey. 2021;1–13.
- 324 11. Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, et al. High
 325 Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A
 326 Study in Jordan and Kuwait among Other Arab Countries. Vaccines. 2021 Jan;9(1):42.
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020
 Dec;383(27):2603–15.
- Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al.
 Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2:

332 333		a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug;396(10249):467–78.
334335336337	14.	Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug;396(10249):479–88.
338339340341	15.	Logunov DY, Dolzhikova I V., Shcheblyakov D V., Tukhvatulin AI, Zubkova O V., Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb;397(10275):671–81.
342 343	16.	Rahul S, Abu BS, Shubhra U, Mriganka S, Saket K, Hamza M, et al. COVID-19 Vaccine Acceptance Among Health Care Workers in the United States. 2021;
344 345 346	17.	Nzaji MK, Ngombe LK, Mwamba GN, Miema JM, Lungoyo CL, Mwimba BL. Acceptability of Vaccination Against COVID-19 Among Healthcare Workers in the Democratic Republic of the Congo. 2020;103–9.
347348349350	18.	Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A. Vaccine hesitancy : the next challenge in the fight against COVID - 19. Eur J Epidemiol [Internet]. 2020;35(8):775–9. Available from: https://doi.org/10.1007/s10654-020- 00671-y
351 352	19.	Chapin-Bardales J, Gee J, Myers T. Reactogenicity Following Receipt of mRNA- Based COVID-19 Vaccines. JAMA. 2021 Apr;383(27):2603–15.
353 354 355 356	20.	Akech GM, Naloli M, Sebwami P, Kazibwe P, Atwikiriize M, Onyait J, et al. Pneumococcal carriage and antibiotic susceptibility patterns in mother-baby pairs in a rural community in Eastern Uganda : a cross-sectional study [version 1 ; peer review : awaiting peer review]. 2020;1–8.
357 358 359	21.	Alhassan RK, Agyei SO, Ansah EK, Gyapong M. COVID - 19 vaccine uptake among health care workers in Ghana : a case for targeted vaccine deployment campaigns in the global south. Hum Resour Health. 2021;1–12.
360 361 362	22.	Erdem H, Lucey DR. Healthcare worker infections and deaths due to COVID-19 : A survey from 37 nations and a call for WHO to post national data on their website. Int J Infect Dis. 2020;(January).

363 364 365	23.	Gagneux-brunon A, Detoc M, Bruel S, Tardy B, Rozaire O. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave : a cross-sectional survey. J Hosp Infect. 2021;108:168–73.
366 367 368	24.	Lazarus J V, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med [Internet]. 2020; Available from: http://dx.doi.org/10.1038/s41591-020-1124-9
369 370	25.	Salali GD. COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey. 2020;(i):26–8.
371372373	26.	Dula J, Mulhanga A, Nhanombe A, Cumbi L, Júnior A, Gwatsvaira J, et al. Covid-19 vaccine acceptability and its determinants in mozambique: An online survey. Vaccines. 2021;9(8):1–10.
374 375	27.	Wang J, Jing R, Lai X, Zhang H, Lyu Y, Knoll MD, et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. :1–14.
376 377 378	28.	Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al. Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. Front Public Heal. 2020;8(July):1–8.
379 380 381	29.	Evridiki P, Petros G, Enkeleint AM, Agathi A, Alexandros A, Evanthia A, et al. Factors influencing nursing students' intention to accept COVID-19 vaccination – A pooled analysis of seven countries. medRxiv Prepr Serv Heal Sci. 2021;
382 383 384	30.	Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021 Mar;

385

VARIABLE	Frequency	Percentage	
Age (Median; IQR), years	31 (25-39)		
18-39	130	76	
≥40	42	24	
Sex			
Female	95	55	
Male	77	45	
Marital status			
eprint doi: https://doi.org/10.1101/2022.07.11.22277490; this w as the author/funder, who have It is made available under a CC-BN	rersion posted July 12, 2022. Th s granted medRxiv a license to c (4 0 International license .	e copyright holder for this preprint display the preprint in perpetuity.	
Married	90	52	
Divorced/Separated	1	1	
Widowed	5	3	
Religion			
Roman catholic	46	27	
Anglican	59	34	
Pentecostal	42	24	
Muslim	24	14	
Others	1	1	
Cadre			
Medical officer	15	9	
Nursing officer	43	25	
Pharmacist	3	2	
Midwife	38	22	
Interns	42	24	
Laboratory technician	15	9	
Specialists	6	3	
Clinical Officers	8	5	
Counsellors	2	1	
Health Facility			
Health center II	13	8	
Health center III	41	24	
Health center IV	20	12	
Mbale Regional Referral	92	53	

Table 1: Demographic characteristic of participants (N=172)

Hospital		
Private Not for Profit	6	3

Table 2: COVID-19 vaccine uptake and reasons for and against among participants

Have you been vaccinated against COVID-19?	Frequency	Percentag
Yes	119	69
No	53	31
Number of COVID-19 vaccine doses received.		
rim doi: https://doi.org/10.1101/2022.07.11.22277490; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; this version posted July 12, 2022. The copyright holder for this p CONTRACTOR OF SECTION 101/2022.07.11.22277490 ; the copyright holder for thol	reprint tuity40	34
Two Doses	79	66
Are you intending to take COVID-19 vaccine in future?		I
Yes, I will get vaccinated	18	34
I am not sure	21	40
No, I will not get vaccinated	14	26
Reasons for COVID-19 vaccine uptake		1
To protect myself from getting COVID-19	95	79
To protect others from getting COVID-19	62	52
I believe in vaccines and immunization	48	40
Government recommendations	64	53
Because my colleague had taken it	7	6
The vaccines are safe	42	35
The vaccines are effective	36	30
It is a social and moral responsibility	25	21
The vaccine was free of charge	38	32
To be able to travel	31	26
I am at high risk of severe disease	30	25
To get rid of the virus and end the pandemic	25	21
It's a job requirement	38	32
It's my obligation as a healthcare worker to motivate others	61	51

Reasons for not getting COVID-19 vaccine		
I don't think it is needed	12	21
I trust my immunity	18	32
I don't know where to get vaccination	1	2
I don't know where to get good/reliable information	4	7
I have heard or read negative information on the vaccine.	30	54
I don't think the vaccine is effective	24	43
I don't think the vaccine is safe/concerned about side effects	31	55
iv preprint doin 1000 (1000 00/1000 11/2022.07 10 22277 0490) this version posted July 12, 2022. The copyright holder for this h was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perp It is made available under a CC-BY 4.0 International license.	prep on t etuity.	16
Had a bad experience with previous vaccinator/health clinic	-	4
Had a bad experience or reaction with previous vaccination	6	11
Someone else told me they/their child had a bad reaction	12	21
Fear of needles	2	4
Religious reasons	4	7
Other beliefs/traditional medicine	3	5

Table 3: Uptake of COVID-19 vaccine and associated factors among the participants

VARIABLE	COVID-19 VACC	COVID-19 VACCINE UPTAKE		
	YES	NO	1	
	Frequency (%)	Frequency (%)		
All participants	119 (69)	53 (31)		
Age, years	1	-		
18-39	82 (70)	48 (91)	0.002	
≥40	37 (30)	5 (9)	0.002	
Sex	I			
Female	66 (55)	29 (55)	0.928	
Male	53 (45)	24 (45)	0.928	
Marital status	I	-		
Single	45 (38)	31 (58)		
Married	68 (57)	22 (42)	0.019	
Separated	6 (5)	0 (0)		

Religion				
Roman Catholic	36 (30)	10 (19)		
Anglican	40 (34)	19 (36)		
Pentecostal	27 (23)	15 (28)	0.454	
Muslim	15 (13)	9 (17)		
Others	1 (1)	0 (0)		
Cadre		I		
Medical officer	11 (9)	4 (8)		
Nursing officer	35 (29)	8 (15)		
not certified by peer review) is the author/funder, wi	this version poster July 12, 2022. The co	pyright holder for this preprint		
It is made available under a C Midwife	C-BY 4.0 international license . 30 (25)	8 (15)		
Interns	15 (13)	27 (51)	<0.001	
Laboratory technician	13 (11)	2 (4)		
Specialists	6 (5)	0 (0)		
Clinical Officers	5 (4)	3 (6)		
Counsellors	2 (2)	0 (0)		
Health Facility		I		
Lower Health Facility	66 (55)	8 (15)	< 0.001	
Hospital	53 (45)	45 (85)		
Perceived likelihood of get	tting COVID-19 in f	uture?		
Not at all	27 (23)	21 (40)		
Slightly	48 (40)	16 (30)	0.072	
Very likely	44 (37)	16 (30)		
Overall worry about COV	/ID-19?	I		
Very worried	49 (41)	19 (36)		
Somewhat worried	52 (44)	21 (40)	0.332	
Not at all worried	18 (15)	13 (25)	-	
Perceived COVID-19 pers	onal risk.	I		
Major risk	71 (60)	33 (62)		
Minor risk	44 (37)	14 (26)	0.072	
No risk at all	4 (3)	6 (11)		
Have you been tested for (COVID-19?	I		
Tested positive	8 (7)	7 (13)	0.060	
Tested negative	60 (50)	17 (32)	0.000	

	COVID-19 managemen			
Yes	66 (55)	23 (43)	0.144	
No	53 (45)	30 (57)		
COVID-19 vaccine give	ves effective protection	T		
Agree	73 (61)	11 (21)		
Neutral	15 (13)	9 (17)	<0.001	
Disagree	31 (26)	33 (62)		
Chronic illness	I	I		
		2 (0)		
print con https://doi.org/10.1101/2022.07.11.22	277490; this version posted July 12, 2022. The councer, who has granted medRxiv a license to disp	opyright holder for this preprint	0.021	

Table 4: Multivariate logistic regression for factors associated with COVID-19 vaccine uptake among participants.

VARIABLE	AOR (95% CI)	P-VALUE
Age		
18-39	1	0.195
40 years and above	2.7 (0.5-12.3)	0.195
Marital Status	•	
Single	0.5 (0.1-1.7)	0.301
Separated	1	
Religion		
Muslim	1	
Roman Catholic	5.6 (0.6-45.8)	0.104
Anglican	0.6 (0.1-4.5)	0.642
Pentecostal	1.2 (0.1-9.8)	0.858
Cadre	•	
Medical officer	2.7 (1.1-65.2)	0.534
Nursing officer	5.9 (0.2-124.6)	0.253
Pharmacist	185.8 (0.4-76.7)	0.089
Midwife	3.6 (0.1-80.1)	0.408
Interns	0.9 (0.0-17.0)	0.984

Laboratory technician	4.5 (0.1-147.3)	0.395
Specialists	1	
Health Facility		
Lower Health Facility	25.9 (5.9-112.7)	< 0.001
Hospital	1	
print doi: https://doi.org/10.1101/2022.07.11.2227740	this version posted July 12, 2022. The convright holder for this prepr	int
s not certified by peer review) is the author/funder, Perceived likenale available under a); this version posted July 12, 2022. The copyright holder for this prepr who has granted medRxiv a license to display the preprint in perpetuity CC-BX 40 memory international mension	
Not at all	0.6 (0.1-3.1)	0.577
Slightly	0.9 (0.2-3.6)	0.948
Very likely	1	
Perceived COVID-19 per	sonal risk.	I
Major risk	14.3 (1.1-181.2)	0.039
Minor risk	25.1 (2.1-290.7)	0.010
No risk at all	1	
Have you been tested for	COVID-19?	I
Tested positive	1.4 (0.1-14.5)	0.731
Tested negative	3.3 (1.0-10.7)	0.046
Haven't tested	1	
COVID-19 vaccine gives	effective protection.	I
Agree	28.3 (6.3-126.1)	< 0.001
Neutral	1.5 (0.2-8.7)	0.635
Disagree	1	
Active involvement in CO	VID-19 management	I
Yes	2.2 (0.6-7.7)	0.193
No	1	
Chronic illness		I
Yes	8.2 (0.8-80.6)	0.070
No	1	




Figure 1: Sources of negative information about COVID-19 vaccination among participants




Figure 2: Occurrence of self-reported side-effects on the different vaccine doses





Figure 3: Severity of self-reported side-effects on the different vaccine doses



C	D	20	40	60	80	100	120
Percentages							

Figure 4: The different self-reported side effects on both COVID-19 vaccine doses




Figure 5: Duration of self-reported side-effects compared among (a) outcomes of previous COVID-19 test (b) possession of chronic illness and (c) age category. Median duration of side-effects is 3 days